scPharmaceuticals issues $10M promissory note to MannKind as bridge loan pending merger

scPharmaceuticals Inc.

Unsecured note for $10M issued to MannKind Corp. on Sept 23, 2025.
Interest at 9.00467% initially, tied to MannKind's SOFR loan rate plus margin.
Maturity on earliest of Sept 23, 2026, termination fee payment, or superior proposal close.
Loan is in connection with the Aug 24, 2025 Merger Agreement for MannKind to acquire scPharmaceuticals.
Covenants mirror existing Perceptive credit agreement; baskets for debt and liens increased 25%.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.